BMRN FY 2023 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.4B+15.4% YoY

Gross Profit

$1.9B78.0% margin

Operating Income

$186M7.7% margin

Net Income

$168M6.9% margin

EPS (Diluted)

$0.88

Cash Flow

Operating Cash Flow

$159M

Free Cash Flow

$63M

Stock-Based Comp.

$207M

Balance Sheet

Total Assets

$6.8B

Total Liabilities

$1.9B

Stockholders' Equity

$5.0B

Cash & Equivalents

$755M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.4B	$2.1B	+15.4%
Gross Profit	$1.9B	$1.6B	+18.5%
Operating Income	$186M	$161M	+15.4%
Net Income	$168M	$142M	+18.4%